Blood test may steer lung cancer therapy in real time

NCT ID NCT04166487

Ongoing Disease control Sponsor: Julia K. Rotow, MD Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 20 times

Summary

This study tests whether a simple blood test can tell if a lung cancer drug (pembrolizumab) is working early on. About 40 people with stage IV non-small cell lung cancer will have blood drawn at different times. If the test shows the drug isn't working well, patients may switch to a combination of pembrolizumab plus chemotherapy. The goal is to personalize treatment and improve outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Boston Medical Center

Boston, Massachusetts, 02118, United States
Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Dana-Farber at Steward St. Elizabeth's Medical Center

Brighton, Massachusetts, 02135, United States
Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) in clinical affiliation with South Shore Hospital

South Weymouth, Massachusetts, 02190, United States

Conditions

Explore the condition pages connected to this study.

METASTATIC NON-SMALL CELL LUNG CANCER NSCLC STAGE IV